AU2020304841B2 - Method for the production of an antibody - Google Patents

Method for the production of an antibody Download PDF

Info

Publication number
AU2020304841B2
AU2020304841B2 AU2020304841A AU2020304841A AU2020304841B2 AU 2020304841 B2 AU2020304841 B2 AU 2020304841B2 AU 2020304841 A AU2020304841 A AU 2020304841A AU 2020304841 A AU2020304841 A AU 2020304841A AU 2020304841 B2 AU2020304841 B2 AU 2020304841B2
Authority
AU
Australia
Prior art keywords
codon
amino acid
antibody
nucleic acid
paired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020304841A
Other languages
English (en)
Other versions
AU2020304841A1 (en
Inventor
Ulrich Goepfert
Stefan Klostermann
Katharina LUTZ
Stefan Seeber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2020304841A1 publication Critical patent/AU2020304841A1/en
Application granted granted Critical
Publication of AU2020304841B2 publication Critical patent/AU2020304841B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020304841A 2019-06-28 2020-06-25 Method for the production of an antibody Active AU2020304841B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
EP19183171.8 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Publications (2)

Publication Number Publication Date
AU2020304841A1 AU2020304841A1 (en) 2021-12-23
AU2020304841B2 true AU2020304841B2 (en) 2024-08-15

Family

ID=67253661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020304841A Active AU2020304841B2 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Country Status (11)

Country Link
US (1) US20220220500A1 (https=)
EP (1) EP3990484A1 (https=)
JP (2) JP7511591B2 (https=)
KR (1) KR102900433B1 (https=)
CN (1) CN113993888B (https=)
AU (1) AU2020304841B2 (https=)
BR (1) BR112021025806A2 (https=)
CA (1) CA3143803A1 (https=)
IL (1) IL289210A (https=)
MX (1) MX2021015193A (https=)
WO (1) WO2020260431A1 (https=)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−２３分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
AU2003206684A1 (en) 2002-02-20 2003-09-09 Novozymes A/S Plant polypeptide production
US20040005600A1 (en) 2002-04-01 2004-01-08 Evelina Angov Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
DK2423315T3 (en) 2006-06-29 2015-04-13 Dsm Ip Assets Bv A method for obtaining enhanced polypeptide expression
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
US7947495B2 (en) * 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
CN109810188A (zh) * 2011-12-21 2019-05-28 弗·哈夫曼-拉罗切有限公司 用于克隆和表达关联抗体可变区基因区段的快速方法
EP2794878B1 (en) * 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6224077B2 (ja) * 2012-04-17 2017-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改変された核酸を用いてポリペプチドを発現させるための方法
SG10201913396RA (en) * 2014-02-28 2020-03-30 Ichnos Sciences SA Expression constructs and methods for selecting host cells expressing polypeptides
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Also Published As

Publication number Publication date
EP3990484A1 (en) 2022-05-04
IL289210A (en) 2022-02-01
BR112021025806A2 (pt) 2022-02-08
JP7511591B2 (ja) 2024-07-05
KR102900433B1 (ko) 2025-12-15
US20220220500A1 (en) 2022-07-14
JP2023183417A (ja) 2023-12-27
CN113993888A (zh) 2022-01-28
MX2021015193A (es) 2022-01-18
JP2022538178A (ja) 2022-08-31
CA3143803A1 (en) 2020-12-30
KR20220024954A (ko) 2022-03-03
AU2020304841A1 (en) 2021-12-23
WO2020260431A1 (en) 2020-12-30
CN113993888B (zh) 2026-01-06
JP7835713B2 (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
US20210024952A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
CA2696809A1 (en) Method of increasing protein titres
US9708636B2 (en) Artificial introns
US10882910B2 (en) Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
US20140248665A1 (en) Novel intron sequences
AU2020304841B2 (en) Method for the production of an antibody
US9249201B2 (en) Heterologous intron within a signal peptide
HK40060841A (zh) 产生抗体的方法
HK40060841B (zh) 产生抗体的方法
TWI457441B (zh) 免疫球蛋白之製造

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)